Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.16%
$13.48
0% positive prob.
5-Day Prediction
-3.23%
$13.20
0% positive prob.
20-Day Prediction
-4.19%
$13.07
0% positive prob.
SEC 8-K filings with transcript text
Feb 24, 2026 · 100% conf.
1D
-1.16%
$13.48
5D
-3.23%
$13.20
20D
-4.19%
$13.07
avns-202602240001606498falseFebruary 24, 202600016064982026-02-242026-02-24
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 24, 2026 (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
Delaware001-3644046-4987888 (State or other jurisdiction of incorporation)(Commission file number)(I.R.S. Employer Identification No.) 5405 Windward Parkway Suite 100 South Alpharetta,Georgia30004 (Address of principal executive offices)(Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock - $0.01 Par ValueAVNSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operation and Financial Condition On February 24, 2026, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits. The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No.Description 99.1 Press Release issued by Avanos Medical, Inc. on February 24, 2026
104Cover Page Interactive Data File (embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 24, 2026By:/s/ John J. Hurley John J. Hurley Controller
Nov 5, 2025
avns-202511050001606498falseNovember 5, 202500016064982025-11-052025-11-05
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
(Exact name of registrant as specified in its charter)
Delaware001-36440 46-4987888 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 5405 Windward Parkway Suite 100 South Alpharetta,Georgia30004 (Address of principal executive offices)(Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of exchange on which registered Common Stock - $0.01 Par ValueAVNSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On November 5, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits.
Exhibit No.Description 99.1 Press release issued by Avanos Medical, Inc. on November 5, 2025
104Cover Page Interactive Data File (embedded within the inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025By:/s/ John J. Hurley John J. Hurley Controller (Principal Accounting Officer)
Aug 5, 2025
avns-202507310001606498falseJuly 31, 202500016064982025-07-312025-07-31
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025
(Exact name of registrant as specified in its charter)
Delaware001-36440 46-4987888 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 5405 Windward Parkway Suite 100 South Alpharetta,Georgia30004 (Address of principal executive offices)(Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of exchange on which registered Common Stock - $0.01 Par ValueAVNSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On August 5, 2025, Avanos Medical, Inc. (the “Company”) issued a press release announcing its results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 1, 2025, the Board of Directors (the “Board”) of the Company appointed David Pacitti to the Board, effective August 1, 2025. The appointment of Mr. Pacitti, who is the Company’s Chief Executive Officer, fills a vacancy on the Board. Mr. Pacitti was not selected pursuant to any arrangement or understanding between him and any other persons. There are no transactions between Mr. Pacitti and the Company that would be reportable under Item 404(a) of Regulation S-K. Mr. Pacitti will not receive any compensation in connection with his service as a member of the Board. On August 1, 2025, the Company appointed Scott Galovan to serve as the Company’s Senior Vice President, Chief Financial Officer, effective August 1, 2025. Mr. Galovan, age 46, has served as the Company’s Senior Vice President, Strategy and Corporate Development since January 2023. He served as the Company’s Vice President, Strategy and Corporate Development from June 2019 until January 2023. Prior to joining the Company in 2013, his experience included serving in senior strategy, finance and M&A roles at Newell Brands, Equity Pacific Partners and Intel Capital. Mr. Galovan was not selected pursuant to any arrangement or understanding between him and any other persons. There are no transactions between Mr. Galovan and the Company that would be reportable under Item 404(a) of Regulation S-K. In connection with Mr. Galovan’s appointment, the Company and Mr. Galovan entered into an offer letter pursuant to which he will receive a base salary of $460,000 per year. In addition, he will be eligible to participate in the Company’s annual cash incentive program with a bonus target of 70% of his base salary and will be eligible for annual long-term incentive grants under the Company’s Long Term Incentive Plan with a target award value for 2026 of $1,600,000. In addition, on August 1, 2025 Mr. Galovan received a special equity award of time-based restricted stock units (“TRSUs”) having a grant date value equal to $500,000. Such TRSUs will vest 3
This page provides Avanos Medical Inc. (AVNS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on AVNS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.